Institutional Conflict News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Roman resigned in February.

<p>Researchers from <a href="http://www.MDAnderson.org">The University of Texas MD&nbsp;Anderson Cancer Center</a> reported promising results in a Phase I/II trial of 37 patients with relapsed or refractory B-cell malignancies who were treated with cord blood-derived <a href="https://www.mdanderson.org/cancerwise/car-nk-therapy-offers-new-treatment-option-for-blood-cancers.h00-159379578.html">chimeric antigen receptor (CAR) natural killer (NK) cell therapy</a> targeting CD19. &nbsp;</p>

EMBARGO UNTIL: May 1, 2023 at 3 PM ET Gene-editing therapy aimed at two targets – HIV-1, the virus that causes AIDS, and CCR5, the co-receptor that helps the virus get into cells – can effectively eliminate HIV infection, new research from the Lewis Katz School of Medicine at Temple University and the University of Nebraska Medical Center (UNMC) shows. The study, published online in the journal The Proceedings of the National Academy of Sciences (PNAS), is the first to combine a dual gene-editing strategy with antiretroviral drugs to cure animals of HIV-1.

/PRNewswire/ -- Cellenkos Inc, a clinical stage biotechnology company focused on the development of allogeneic, off-the-shelf, T regulatory cell therapies...

-Clinical Trial of PRAME-Targeting Immunotherapy ISA103 in Rare Ocular Cancer to be Conducted at MD Anderson Cancer Center- OEGSTGEEST, Netherlands and HOUSTON, Jan. 4, 2023 /PRNewswire/